https://www.oncologynurseadvisor.com Wed, 03 Jan 2024 19:27:32 +0000 en-US hourly 1 https://wordpress.org/?v=6.4.3 https://www.oncologynurseadvisor.com/wp-content/uploads/sites/13/2024/01/cropped-CTA-ONA-HEM-favicon-32x32.png https://www.oncologynurseadvisor.com 32 32 https://www.oncologynurseadvisor.com/reports/olverembatinib-cml-tki-resistant-chronic-phase-efs/ Fri, 15 Dec 2023 15:40:00 +0000 https://www.oncologynurseadvisor.com/?p=114906 Olverembatinib improved event-free survival over best available therapy in patients with TKI-resistant chronic phase CML in a phase 2 trial.]]> https://www.oncologynurseadvisor.com/home/cancer-types/general-oncology/pembrolizumab-demonstrates-activity-in-patients-with-advanced-nets/ Thu, 17 Aug 2023 14:20:00 +0000 https://www.oncologynurseadvisor.com/?p=109941 Pembrolizumab has demonstrated significant efficacy in patients with advanced neuroendocrine tumors, according to researchers.]]> https://www.oncologynurseadvisor.com/home/cancer-types/general-oncology/failed-oncology-trials-may-cost-up-to-60-billion-per-year/ Mon, 07 Aug 2023 14:20:00 +0000 https://www.oncologynurseadvisor.com/?p=109606 Researchers have estimated that failed oncology trials cost about $50 billion to $60 billion each year.]]>